BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sousa AR, Oliveira AV, Oliveira MJ, Sarmento B. Nanotechnology-based siRNA delivery strategies for metastatic colorectal cancer therapy. International Journal of Pharmaceutics 2019;568:118530. [DOI: 10.1016/j.ijpharm.2019.118530] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Jebelli A, Baradaran B, Mosafer J, Baghbanzadeh A, Mokhtarzadeh A, Tayebi L. Recent developments in targeting genes and pathways by RNAi-based approaches in colorectal cancer. Med Res Rev 2021;41:395-434. [PMID: 32990372 DOI: 10.1002/med.21735] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Liu N, Wu C, Jia R, Cai G, Wang Y, Zhou L, Ji Q, Sui H, Zeng P, Xiao H, Liu H, Huo J, Feng Y, Deng W, Li Q. Traditional Chinese Medicine Combined With Chemotherapy and Cetuximab or Bevacizumab for Metastatic Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Front Pharmacol 2020;11:478. [PMID: 32372960 DOI: 10.3389/fphar.2020.00478] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
3 Zhao T, Wu W, Sui L, Huang Q, Nan Y, Liu J, Ai K. Reactive oxygen species-based nanomaterials for the treatment of myocardial ischemia reperfusion injuries. Bioact Mater 2022;7:47-72. [PMID: 34466716 DOI: 10.1016/j.bioactmat.2021.06.006] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 30.0] [Reference Citation Analysis]
4 Zuo X, Chen Z, Gao W, Zhang Y, Wang J, Wang J, Cao M, Cai J, Wu J, Wang X. M6A-mediated upregulation of LINC00958 increases lipogenesis and acts as a nanotherapeutic target in hepatocellular carcinoma. J Hematol Oncol 2020;13:5. [PMID: 31915027 DOI: 10.1186/s13045-019-0839-x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 75] [Article Influence: 35.5] [Reference Citation Analysis]
5 Zheng X, Zhu Y, Fei W, Zhao Y, Liu Y, Yan J, Chen Y, Zheng C, Zhang M. Redox-Responsive and Electrically Neutral PLGA Nanoparticles for siRNA Delivery in Human Cervical Carcinoma Cells. J Pharm Innov. [DOI: 10.1007/s12247-021-09592-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Mohammadinejad R, Dehshahri A, Sagar Madamsetty V, Zahmatkeshan M, Tavakol S, Makvandi P, Khorsandi D, Pardakhty A, Ashrafizadeh M, Ghasemipour Afshar E, Zarrabi A. In vivo gene delivery mediated by non-viral vectors for cancer therapy. J Control Release 2020;325:249-75. [PMID: 32634464 DOI: 10.1016/j.jconrel.2020.06.038] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 19.0] [Reference Citation Analysis]
7 Al-Nemrawi NK, AbuAlSamen MM, Alzoubi KH. Awareness about nanotechnology and its applications in drug industry among pharmacy students. Curr Pharm Teach Learn 2020;12:274-80. [PMID: 32273062 DOI: 10.1016/j.cptl.2019.12.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
8 Zhang L, Yu R, Li C, Dang Y, Yi X, Wang L. Circ_0026416 downregulation blocks the development of colorectal cancer through depleting MYO6 expression by enriching miR-545-3p. World J Surg Oncol 2021;19:299. [PMID: 34645476 DOI: 10.1186/s12957-021-02407-y] [Reference Citation Analysis]
9 Aghamiri S, Raee P, Talaei S, Mohammadi-Yeganeh S, Bayat S, Rezaee D, Ghavidel AA, Teymouri A, Roshanzamiri S, Farhadi S, Ghanbarian H. Nonviral siRNA delivery systems for pancreatic cancer therapy. Biotechnol Bioeng 2021. [PMID: 34170520 DOI: 10.1002/bit.27869] [Reference Citation Analysis]
10 El Jundi A, Morille M, Bettache N, Bethry A, Berthelot J, Salvador J, Hunger S, Bakkour Y, Belamie E, Nottelet B. Degradable double hydrophilic block copolymers and tripartite polyionic complex micelles thereof for small interfering ribonucleic acids (siRNA) delivery. Journal of Colloid and Interface Science 2020;580:449-59. [DOI: 10.1016/j.jcis.2020.07.057] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Xia Y, Tang G, Guo M, Xu T, Chen H, Lin Z, Li Y, Chen Y, Zhu B, Liu H, Cao J. Silencing KLK12 expression via RGDfC-decorated selenium nanoparticles for the treatment of colorectal cancer in vitro and in vivo. Mater Sci Eng C Mater Biol Appl 2020;110:110594. [PMID: 32204058 DOI: 10.1016/j.msec.2019.110594] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
12 Bao X, Zeng J, Huang H, Ma C, Wang L, Wang F, Liao X, Song X. Cancer-targeted PEDF-DNA therapy for metastatic colorectal cancer. Int J Pharm 2020;576:118999. [PMID: 31893541 DOI: 10.1016/j.ijpharm.2019.118999] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
13 Vinchhi P, Patel MM. Triumph against cancer: invading colorectal cancer with nanotechnology. Expert Opin Drug Deliv 2021;18:1169-92. [PMID: 33567909 DOI: 10.1080/17425247.2021.1889512] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Zuo J, Zhang Z, Li M, Yang Y, Zheng B, Wang P, Huang C, Zhou S. The crosstalk between reactive oxygen species and noncoding RNAs: from cancer code to drug role. Mol Cancer 2022;21:30. [PMID: 35081965 DOI: 10.1186/s12943-021-01488-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
15 Diego-gonzález L, Fernández-carrera A, Igea A, Martínez-pérez A, Real Oliveira MECD, Gomes AC, Guerra C, Barbacid M, González-fernández Á, Simón-vázquez R. Combined Inhibition of FOSL-1 and YAP Using siRNA-Lipoplexes Reduces the Growth of Pancreatic Tumor. Cancers 2022;14:3102. [DOI: 10.3390/cancers14133102] [Reference Citation Analysis]